Trials / Unknown
UnknownNCT05103501
Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy
Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of esophageal squamous cell carcinoma patients nonresponding to initial neoadjuvant chemoradiotherapy. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab） | immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2023-09-30
- Completion
- 2024-09-30
- First posted
- 2021-11-02
- Last updated
- 2021-11-02
Source: ClinicalTrials.gov record NCT05103501. Inclusion in this directory is not an endorsement.